BACKGROUND: Chronic kidney disease (CKD) is estimated that by 2040, it will be the 5th highest cause of years of life lost globally due to the aging population and the rising prevalence of age-related diseases such as hypertension and diabetes. Therefore, a deep comprehension of the biological and molecular mechanisms underlying kidney fibrosis is urgently needed to facilitate the development of new therapeutic strategies that can hinder disease progression and simultaneously address the comorbidities associated with CKD. MAIN BODY: In the last years numerous studies have elucidated the complex interplay of various cellular and molecular pathways that contribute to the progression of kidney fibrosis. As a result, several promising therapeutic targets have been identified, paving the way for innovative treatment strategies. These include endogenous (Dickkopf-1, Klotho, and secreted frizzled-related proteins) and exogenous (ICG-001 and relaxin) modulators of the WNT/β-catenin pathway; inhibitors of TGF-β (BMP-7, ncRNA, fresolimumab); sphingosine analogs (fingolimod). In addition to these indirect approaches, therapies with direct antifibrotic activity have also gained significant attention in the field. Among these alternatives, SGLT2 inhibitors and finerenone have emerged as particularly promising options due to the favorable outcomes observed in large-scale clinical trials. These studies have highlighted their effectiveness in slowing disease progression and improving patient outcomes. CONCLUSIONS: Despite the encouraging results, additional research is necessary to fully assess the protective roles of these treatments in various clinical contexts. This review aims to synthesize the available data and current insights into this important issue.

Emerging therapeutic pipelines on kidney fibrosis: challenges in translational research / Granata, S., Barberio, L., D'Agostino, R., Sorace, F., Leone, F., Pellegrino, D., Stallone, G., Provenzano, M., Zaza, G.. - In: JOURNAL OF TRANSLATIONAL MEDICINE. - ISSN 1479-5876. - (2026). [10.1186/s12967-026-07796-w]

Emerging therapeutic pipelines on kidney fibrosis: challenges in translational research

Zaza G.
2026

Abstract

BACKGROUND: Chronic kidney disease (CKD) is estimated that by 2040, it will be the 5th highest cause of years of life lost globally due to the aging population and the rising prevalence of age-related diseases such as hypertension and diabetes. Therefore, a deep comprehension of the biological and molecular mechanisms underlying kidney fibrosis is urgently needed to facilitate the development of new therapeutic strategies that can hinder disease progression and simultaneously address the comorbidities associated with CKD. MAIN BODY: In the last years numerous studies have elucidated the complex interplay of various cellular and molecular pathways that contribute to the progression of kidney fibrosis. As a result, several promising therapeutic targets have been identified, paving the way for innovative treatment strategies. These include endogenous (Dickkopf-1, Klotho, and secreted frizzled-related proteins) and exogenous (ICG-001 and relaxin) modulators of the WNT/β-catenin pathway; inhibitors of TGF-β (BMP-7, ncRNA, fresolimumab); sphingosine analogs (fingolimod). In addition to these indirect approaches, therapies with direct antifibrotic activity have also gained significant attention in the field. Among these alternatives, SGLT2 inhibitors and finerenone have emerged as particularly promising options due to the favorable outcomes observed in large-scale clinical trials. These studies have highlighted their effectiveness in slowing disease progression and improving patient outcomes. CONCLUSIONS: Despite the encouraging results, additional research is necessary to fully assess the protective roles of these treatments in various clinical contexts. This review aims to synthesize the available data and current insights into this important issue.
2026
finerenone; Kidney fibrosis; Mineralocorticoid receptor antagonists; SGLT2 inhibitors; Shh pathway; Sphingosine analogs; TGF-beta; WNT/beta catenin
01 Pubblicazione su rivista::01a Articolo in rivista
Emerging therapeutic pipelines on kidney fibrosis: challenges in translational research / Granata, S., Barberio, L., D'Agostino, R., Sorace, F., Leone, F., Pellegrino, D., Stallone, G., Provenzano, M., Zaza, G.. - In: JOURNAL OF TRANSLATIONAL MEDICINE. - ISSN 1479-5876. - (2026). [10.1186/s12967-026-07796-w]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1775739
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact